Pfizer completes acquisition of Anacor Pharmaceuticals
The Anacor acquisition adds crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, to Pfizer's pipeline...
List view / Grid view
The Anacor acquisition adds crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, to Pfizer's pipeline...
13 July 2015 | By Victoria White
Anacor has announced positive preliminary top-line results from its two Phase 3 pivotal studies of crisaborole in atopic dermatitis (eczema)...